Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma

Noel Laudi, Mukta Arora, Linda Burns, Philip McGlave, Jeffrey Miller, Gerald Bohac, Tyson Rogers, Juliet Barker, James Coad, Daniel Weisdorf

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Conventional treatment of mantle cell lymphoma (MCL) yields modest responses and short remissions. We report 30 hematopoietic stem cell transplants (HSCT) for MCL: 13 autologous, 10 allogeneic myeloablative, and 7 nonablative. After a median 1.2 years from diagnosis (range 0.5 to 4.7) and a median of 2 pre-HSCT chemotherapeutic regimens (range 1 to 5), their median age at HSCT was 52 years (range 37 to 67). Eleven patients (41%) were in first remission, 11 (41%) were in second remission, and 7 (25%) had resistant disease. Four died early. Nineteen achieved CR (83%) and 4 PR (17%). With median 2.7 years of follow-up, 5-year overall survival (OS) was 42% (95% Cl 11-73%) after autologous versus allogeneic at 49% (95% Cl 22-76%). Five-year progression-free survival (PFS) was 31% (95% Cl 3-59%) and 50% (95% Cl 24-76%) for autologous and allogeneic HSCT, respectively. Fourteen died: 3 from sepsis, 1 acute GVHD, 10 MCL. No autologous transplant-related deaths occurred. Allogeneic transplant-related mortality was 29% (95% Cl 6-52%) at 1 and 5 years. HSCT for MCL can yield extended disease control and long-term survival.

Original languageEnglish (US)
Pages (from-to)519-524
Number of pages6
JournalAmerican Journal of Hematology
Issue number7
StatePublished - Jul 2006


  • Allogeneic
  • Autologous
  • Mantle cell lymphoma
  • Stem cell transplant


Dive into the research topics of 'Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma'. Together they form a unique fingerprint.

Cite this